| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Koninklijke Philips N.V. NY Registry Shares$26.53
+0.05 (+0.19%)
Market Cap
26.06 B
EPS
1.18
P/E Ratio
22.33 $
Value Trade
23.33 M
1.19 %
Week
-6.21 %
1 Month
0.59 %
3 Month
-7.09 %
6 Month
-49.18 %
5 Year
722.04 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
151.28 K
52 Week Range
23.85 - 32.24
% held by Insiders
0.01 %
% held by Institutions
5.17 %
Enterprise Value
32.18 B
Total Shares
982.88 M
Short %
0.19 %
Float Shares
771.54 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PHG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PHG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PHG▲ +0.2%today
Philips Avent introduces new automated SMS-based tool to help moms activate their village during postpartum
Philips Avent has launched the Share the Care Connector, an SMS-based tool aimed at helping new mothers organize support from their community during the postpartum period. The initiative, developed in partnership with March of Dimes, addresses the challenges new moms face in asking for help. The tool allows mothers to invite supporters, customize their needs, and receive actionable support suggestions, thereby reducing the emotional burden of coordination.
Read more →PHGAI Moves from Promise to Practice, Transforming Clinical Care Across the U.S., Philips Report Finds
A recent report by Philips indicates that artificial intelligence (AI) is transitioning from theoretical promise to practical application in clinical care across the United States. The findings suggest significant advancements in healthcare technology, showcasing the transformative potential of AI in improving patient outcomes and operational efficiency.
Read more →PHGPhilips receives FDA 510(k) clearance for Elevate Plus for EPIQ Elite and Affiniti, delivering AI advancements in general imaging ultrasound
Philips has received FDA 510(k) clearance for its Elevate Plus system, which enhances the EPIQ Elite and Affiniti ultrasound platforms with AI-driven automation. This technology aims to improve imaging quality, reduce scanning time, and support clinicians in delivering consistent care. The system integrates advanced features like Koios AI for rapid lesion classification and modular upgrades for long-term value.
Read more →PHGPhilips announces exchange ratio for 2025 dividend
Philips has announced an exchange ratio of 1 new common share for every 26.9341 existing shares for its 2025 dividend, calculated based on recent trading prices. Shareholders can choose between receiving dividends in shares or cash, with 43.8% opting for cash. The total number of new shares to be issued is approximately 19.96 million.
Read more →PHGPhilips Lumea IPL 9000 Series and Philips Sonicare 6400 Electric Toothbrush Selected as Good Housekeeping 2026 Beauty Awards Winners
Philips has announced that its Lumea IPL 9000 Series and Sonicare 6400 Electric Toothbrush have been awarded the Good Housekeeping 2026 Beauty Awards. This recognition highlights the effectiveness and innovation of these products in the beauty and dental care sectors.
Read more →PHGPhilips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm
Philips, in collaboration with Cuviva and Vingmed, has been awarded a contract to implement a hospital-at-home initiative in Region Stockholm. This program will enable remote monitoring for complex patients, allowing them to receive hospital-level care at home. The initiative aims to improve patient outcomes while addressing healthcare system pressures and is set to serve over 2 million residents.
Read more →PHGPhilips delivers strong order intake, comparable sales growth and margin expansion in Q1; 2026 outlook reiterated
Philips reported a strong start to 2026 with a 6% increase in comparable order intake and a 4% rise in group sales, totaling EUR 3.9 billion. The adjusted EBITA margin improved to 9.0%, driven by higher sales despite challenges from tariffs and cost inflation. The company reiterated its full-year outlook, projecting sales growth of 3%-4.5% and a focus on strategic innovations in health technology.
Read more →PHGFDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair
Philips has received FDA 510(k) clearance for its AI-powered DeviceGuide, designed to assist in minimally invasive mitral valve repairs. This software integrates with the Azurion platform, providing real-time imaging and navigation support to enhance procedural accuracy. Developed in collaboration with Edwards Lifesciences, DeviceGuide aims to streamline complex cardiac interventions and improve patient outcomes.
Read more →PHGPhilips launches IntraSight Plus to simplify coronary interventions and advance precision care
Philips has launched IntraSight Plus, an interventional guidance platform cleared for use in the USA and Europe. This platform combines diagnostic and treatment planning tools to enhance workflow efficiency in coronary procedures. It aims to simplify complex interventions and improve patient outcomes by integrating various imaging and assessment technologies into one system.
Read more →PHGPhilips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant
Philips has been recognized as the leading medical technology company by the European Patent Office, filing 1,289 patent applications in 2025. The company focuses on integrating hardware, software, and AI to enhance healthcare solutions. Philips aims to improve the lives of 2.5 billion people annually by 2030, emphasizing innovation in underserved communities.
Read more →PHGPhilips Sonicare declares World Oral Health Night, spotlighting what manual brushing leaves behind
Philips Sonicare is declaring World Oral Health Night on March 20th to highlight the inadequacies of manual brushing in removing plaque. The initiative includes a public installation in New York City that showcases the hidden effects of bacteria growth during the night. Sonicare's technology is designed to enhance oral health by removing significantly more plaque than manual brushing, thereby promoting overall wellness.
Read more →PHGPhilips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments
Philips has launched Rembra, a next-generation CT system, at ECR 2026, designed to enhance diagnostic speed and patient access in acute imaging environments. With advanced image reconstruction technology, Rembra can produce up to 106 images per second and handle 270 patients daily. Its 85 cm bore accommodates complex cases, improving patient comfort and reducing rescans. The system integrates AI to streamline workflows and enhance diagnostic confidence.
Read more →PHGSHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments
The SHERPA research consortium, led by Philips, has launched seven clinical studies aimed at validating AI-assisted technologies for minimally invasive treatments of brain aneurysms and liver tumors. With a budget of EUR 21.5 million, the project seeks to address staffing shortages and improve workflow efficiency in interventional radiology. The studies will be conducted across multiple prestigious medical centers in Europe.
Read more →PHGPhilips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort
Philips has launched the InkSpace Imaging Snuggle pediatric MRI coil for its 3.0T MRI systems, aimed at improving comfort and imaging quality for young patients. The coil's flexible design enhances the MRI experience, making it less intimidating for children. Recently cleared by the FDA, the Snuggle coil is now available in the U.S. with plans for future expansion.
Read more →PHGSEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
Royal Philips announced that the SEISMIC consortium has secured a EUR 23.5 million grant from the Innovative Health Initiative to enhance minimally invasive brain treatments. The project aims to integrate advanced imaging with surgical techniques, focusing on improving outcomes for patients with critical neurological conditions. This initiative will support eight clinical studies over five years, fostering innovation in neurosurgery.
Read more →PHG▲ +11.1%on this newsshared move
Philips delivers full year 2025 with growth acceleration, strong margin expansion and solid cash flow; announces 2026-2028 targets at Capital Markets Day
Philips reported strong financial performance for 2025, with notable growth in order intake and sales across all segments. The company successfully launched new healthcare innovations and achieved significant margin expansion despite facing tariff challenges. Looking ahead, Philips aims to drive profitable growth with a focus on customer-centric innovation and operational excellence, while navigating an uncertain macro-environment.
Read more →PHG▲ +11.1%on this newsshared move
Philips proposes to re-appoint CEO Roy Jakobs
Royal Philips has proposed the re-appointment of Roy Jakobs as CEO, recognizing his leadership since 2022. The Supervisory Board commended his efforts in enhancing financial resilience and fostering a culture focused on patient safety and innovation. The proposal will be voted on at the upcoming Annual General Meeting on May 8, 2026.
Read more →PHGPreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment
Royal Philips announced that the PreciseOnco consortium received a EUR 14.9 million grant from the EU's Innovative Health Initiative to enhance precision cancer treatment. The project will integrate advanced medical imaging, robotic assistance, and minimally invasive therapies over five years, including five clinical studies. This initiative aims to improve cancer care efficiency and patient outcomes.
Read more →PHGPhilips named a Clarivate Top 100 Global Innovator for the 13th consecutive year
Royal Philips has been named a Clarivate Top 100 Global Innovator for the 13th consecutive year, reaffirming its leadership in health technology. The company invests over EUR 1.7 billion annually in R&D, focusing on AI-enabled technologies and advanced imaging. CEO Roy Jakobs emphasized the commitment to improving healthcare outcomes and expanding access through innovative solutions.
Read more →PHGEmergency Care Holdings Acquires Philips Emergency Care Business, Launching Global Emergency Care Platform
Emergency Care Holdings has completed the acquisition of Philips Emergency Care, now operating as Heartstream. This strategic move aims to create a global emergency care platform, enhancing access to advanced medical technologies. The acquisition is expected to drive innovation and growth in the emergency medical products sector, which exceeds $26 billion globally.
Read more →PHGPhilips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI
Royal Philips has announced its acquisition of SpectraWAVE, Inc., enhancing its capabilities in coronary intravascular imaging and physiological assessment. This acquisition aims to integrate advanced AI technologies into Philips' existing portfolio, improving patient outcomes for those with coronary artery disease. The partnership emphasizes the importance of innovation in minimally invasive procedures.
Read more →PHGPhilips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision
Philips has launched Verida, the first detector-based spectral CT powered by AI, at RSNA 2025. This innovative technology enhances diagnostic precision by optimizing imaging quality and workflow efficiency. Verida can perform scans faster and with reduced radiation doses, potentially transforming cardiac imaging and other clinical applications. The system will be available in select markets starting in 2026.
Read more →PHGPhilips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform
Philips has launched the BlueSeal Horizon, the first helium-free 3.0T MRI platform, at RSNA 2025. This innovative system combines advanced AI technology to enhance diagnostic precision and streamline workflows. The platform aims to eliminate the need for helium refills, reducing installation complexity and lifecycle risks, while providing high-resolution imaging capabilities.
Read more →PHGNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN, ANY JURISDICTION WHERE SUCH RELEASE
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN, ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL Koninklijke Philips N.V. Announces Pricing Terms of Any and All Tender Offer for Certain Outstandin
Read more →PHGPress Information
THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL, OR ANY SOLICITATION OF AN OFFER TO PURCHASE, ANY SECURITIES OF PHILIPS. Philips launches offering of Green and Sustainability Innovation Notes and a Ser
Read more →PHGNONQUALIFIED STOCK PURCHASE PLAN Appendix A Plan Specifications for Koninklijke Philips Electronics N.V. Nonqualified Stock Purchase Plan Plan Item Specifications Plan Name Koninklijke Philips Electronics N.V. Nonqualifi
Specifications for Koninklijke Philips Electronics N.V. Nonqualified Stock Purchase Plan Plan Name Koninklijke Philips Electronics N.V. Nonqualified Stock Purchase Plan Effective Date August 1, 2000 Definitions Affiliate Present or future subsidiary corporation of the Company,
Read more →PHGANNUAL REPORT exv99w1 Table of Contents A new approach to annual reporting Philips is striving to combine timely reporting of its annual financial results with full disclosure and transparency. This year, Philips has aga
Table of Contents A new approach to annual reporting Philips is striving to combine timely reporting of its annual financial results with full disclosure and transparency. This year, Philips has again accelerated the reporting of its annual financial results. The performance
Read more →Competitive Position
How PHG ranks across every disease it competes inCompetitive Position is a premium feature
See how PHG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial